Overall, HCC cells with high CTSE expression releases a higher level of DCP, which will affect anti-PD-1 immunotherapy by inhibiting the intra-tumoral infiltration of CD8+ and IFNγ+CD8+ T cells. Here, CD8A is linked to hepatocellular carcinoma.